This extensive review of the current knowledge on the mechanistic roles of nuclear sirtuins (SIRT1, 6, and 7), cytoplasmic sirtuins (SIRT2), and mitochondrial sirtuins (SIRT3, 4, and 5) has shown that breast and prostate cancer cells or tissues portray different expression patterns of the various types of sirtuins to aid their tumorigenic phenotypes and potentiate their progression through various carcinogenic stages. The gene discussed is SIRT2; the disease is prostate carcinoma.